Physiogenex will be presenting a poster on Monday, June 10, 2019 12:00 PM – 01:00 PM at the American Diabetes Association’s 79th Scientific Sessions on June 7-11 in San Francisco. Dr. François Briand, our Director of Research and Business Development, will be present...read more
PRECLINICAL CRO SERVICES FOR DRUGS TARGETING METABOLIC DISORDERS
Physiogenex provides preclinical in vivo and ex vivo CRO services with more than 15 years of expertise in evaluating drugs targeting metabolic disorders such as obesity, diabetes, NASH, fibrosis, diabetic nephropathy, cardiovascular complications, dyslipidemia and atherosclerosis.
We develop in-house and gold standard preclinical models in our cutting-edge facilities near Toulouse, France.
Along with our preclinical CRO services, we offer consulting services adapted to the specific needs of our clients. Our metabolic diseases experts offer their many years of experience in drug development to help you design and run efficient and cost-effective studies to shorten your product’s time to market.
STATE OF THE ART CRO FACILITIES
Physiogenex is located near Toulouse (France) in brand new facilities . Our technical platform is equipped with all appropriate devices to ensure high quality CRO services and reliable study results to our clients.
THEY TRUST US
We work with more than 100 biopharmaceutical, nutraceutical and agrifood companies
LATEST NEWS ABOUT PHYSIOGENEX
79th American Diabetes Association Scientific Sessions (June 7-11, 2019) in San Francisco, California.
Physiogenex will attend the 2019 EAS Congress on May 26-29, 2019 in Maastricht. Dr. François Briand, our Director of Research and Business Development, will be present at this event. He will be happy to discuss with you about your preclinical atherosclerosis projects....read more
Physiogenex will attend the 2019 edition of the NASH Annual Summit on April 23 and 24th in Boston. The NASH Summit in Boston is one a leading industry forum for advancing the development of successful NASH therapeutics. This event is focused on discovery through to...read more